Dinko Rekić

Citado por

	Total	Desde 2019
Citas	734	542
Índice h	11	10
Índice i10	13	10

140

105

201120122013201420152016201720182019202020212022202320246 12 28 27 17 19 31 48 50 54 97 112 124 103

Acceso público

Ver todo

5 artículos

0 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Jane KnöchelUniversity of Potsdam, AstraZenecaDirección de correo verificada de uni-potsdam.de
Ping Zhao, PhDSenior Program Officer, Bill&Melinda Gates Foundation; PBPK Lead/Senior Pharmacologist, FDA; PfizerDirección de correo verificada de gatesfoundation.org
Michael AshtonGothenburgDirección de correo verificada de gu.se
Youwei BiUS FDADirección de correo verificada de fda.hhs.gov
Hae-chang RimKorea UniversityDirección de correo verificada de nlp.korea.ac.kr
Kenta YoshidaGenentechDirección de correo verificada de gene.com
Bengt HamrénCVMD QCP Lead, AstraZenecaDirección de correo verificada de waehlby.com
Aleksandra GaletinProfessor of Translational Pharmacokinetics, University of Manchester, UKDirección de correo verificada de manchester.ac.uk
gustafsson llprofessor i klinisk farmakologi, Karolinska Institutet StockholmDirección de correo verificada de ki.se
Eleni AklilluProfessor of Tropical Pharmacology, Karolinska InstitutetDirección de correo verificada de ki.se
Paul WaakoProfessor of Pharmacology and Therapuetics Busitema UniversityDirección de correo verificada de adm.busitema.ac.ug
Eva Hurt-camejoChief Scientist, R&D BiophaPharmaceuticals, AstraZeneca. Adj.Professor, Karolisnka InstituteDirección de correo verificada de astrazeneca.com
Magnus GisslénProfessor of Infectious Diseases, Sahlgrenska Academy at University of GothenburgDirección de correo verificada de infect.gu.se
Oskar ClewePharmetheus ABDirección de correo verificada de pharmetheus.com
Jacob LeanderClinical Pharmacology & Pharmacometrics, AstraZeneca R&DDirección de correo verificada de astrazeneca.com
Jennifer SchumiStatistics TA Head, Immunology/Biosimilars, Teva PharmaceuticalsDirección de correo verificada de tevapharm.com
Anshu MaratheDirector, NovartisDirección de correo verificada de novartis.com
Peter GennemarkResearcher at AstraZenecaDirección de correo verificada de astrazeneca.com
Ivan AzarovM&S DecisionsDirección de correo verificada de msdecisions.ru
Ulrika SH SimonssonUppsala UniversityDirección de correo verificada de farmbio.uu.se

Seguir

Dinko Rekić

Drug Development Leader at Alexion

Dirección de correo verificada de alexion.com - Página principal

Pharmacometrics Clinical Pharmacology Drug Development QT prolongation Drug-Drug Interactions


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis CBA Paterniti MO, Bi Y, Rekić D, Wang Y, Karimi-Shah BA Annals of the American Thoracic Society, 2017	167	2017
An oral antisense oligonucleotide for PCSK9 inhibition P Gennemark, K Walter, N Clemmensen, D Rekić, CAM Nilsson, ... Science Translational Medicine 13 (593), eabe9117, 2021	102	2021
Clinical drug–drug interaction evaluations to inform drug use and enable drug access D Rekić, KS Reynolds, P Zhao, L Zhang, K Yoshida, M Sachar, MP Miller, ... Journal of pharmaceutical sciences 106 (9), 2214-2218, 2017	78	2017
In vitro–in vivo extrapolation of metabolism-and transporter-mediated drug–drug interactions—overview of basic prediction methods K Yoshida, P Zhao, L Zhang, DR Abernethy, D Rekić, KS Reynolds, ... Journal of pharmaceutical sciences 106 (9), 2209-2213, 2017	74	2017
Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine L Barregard, D Rekić, M Horvat, L Elmberg, T Lundh, O Zachrisson Toxicological Sciences 120 (2), 499-506, 2011	64	2011
In silico prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype D Rekić, D Röshammar, J Mukonzo, M Ashton British journal of clinical pharmacology 71 (4), 536-543, 2011	54	2011
HIVAIDS Patients Display Lower Relative Bioavailability of Efavirenz than Healthy Subjects JK Mukonzo, S Nanzigu, D Rekić, P Waako, D Roshammar, M Ashton, ... Clinical pharmacokinetics 50 (8), 531-540, 2011	39	2011
Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy D Rekić, O Clewe, D Röshammar, L Flamholc, A Sönnerborg, ... The AAPS journal 13 (4), 598-605, 2011	20	2011
QT prolongation risk assessment in oncology: lessons learned from small‐molecule new drug applications approved during 2011‐2019 S Cohen‐Rabbie, AC Berges, D Rekić, J Parkinson, C Dota, ... The Journal of Clinical Pharmacology 61 (8), 1106-1117, 2021	14	2021
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval D Rekić, I Azarov, J Knöchel, V Sokolov, C Nilsson, L Wernevik, D Han, ... British Journal of Clinical Pharmacology 88 (11), 4839-4844, 2022	13	2022
Model based design and analysis of phase II HIV-1 trials D Rekić, D Röshammar, USH Simonsson Journal of pharmacokinetics and pharmacodynamics 40, 487-496, 2013	12	2013
Etesian: a phase 2B study of the efficacy, safety and tolerability of Azd8233, a Pcsk9-targeted antisense oligonucleotide, in patients with dyslipidemia MJ Koren, A Hofherr, J Schumi, D Rekic, J Knochel, CAM Nilsson, ... Journal of the American College of Cardiology 79 (9_Supplement), 1475-1475, 2022	11	2022
Pharmacokinetics of roxadustat: a population analysis of 2855 dialysis-and non-dialysis-dependent patients with chronic kidney disease D Rekić, V Kerbusch-Herben, M Någård, J Chou, J Huang, C Bradley, ... Clinical Pharmacokinetics 60, 759-773, 2021	11	2021
Dapagliflozin pharmacokinetics is similar in adults with type 1 and type 2 diabetes mellitus J Melin, W Tang, D Rekić, B Hamrén, RC Penland, DW Boulton, ... The Journal of Clinical Pharmacology 62 (10), 1227-1235, 2022	9	2022
A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated … J Leander, M Sunnåker, D Rekić, S Aksenov, UG Eriksson, S Johansson, ... Journal of Pharmacokinetics and Pharmacodynamics 48, 525-541, 2021	9	2021
A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients Y Bi, D Rekić, MO Paterniti, J Chen, A Marathe, BA Chowdhury, ... Journal of pharmacokinetics and pharmacodynamics 48, 55-67, 2021	8	2021
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II J Knöchel, C Nilsson, B Carlsson, L Wernevik, A Hofherr, P Gennemark, ... CPT: pharmacometrics & systems pharmacology 11 (12), 1569-1577, 2022	6	2022
Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data Y Aoki, CS Cabrera, M Ouwens, K Bamberg, J Nyström, I Raz, BM Scirica, ... Plos one 17 (6), e0269970, 2022	6	2022
Concentration‐QT modelling in early clinical oncology settings: Simulation evaluation of performance G Cantet, A Berges, R O'Sullivan, S Cohen‐Rabbie, C Dota, V Dubois, ... British Journal of Clinical Pharmacology 88 (3), 1010-1019, 2022	5	2022
Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations V Voronova, M Cullberg, P Delff, J Parkinson, C Dota, G Schiavon, ... British Journal of Clinical Pharmacology 88 (2), 858-864, 2022	5	2022

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores